LONG-ACTING FORMS OF HIV PREVENTION

For some people, long-acting forms of HIV prevention may be more desirable than a daily pill.

HIV prevention today — and in the future.

Taking an oral dose of the medication Truvada once a day, every day can prevent HIV infection.

NIAID-funded researchers are developing and testing alternative HIV prevention products that could be inserted, injected, infused or implanted from ONCE A MONTH... …TO ONCE A YEAR in people who commit to use the products on an ongoing basis.

NIAID is funding research on 4 types of long-acting HIV prevention.

<table>
<thead>
<tr>
<th>INTRAVAGINAL RING (IVR)</th>
<th>IMPLANT</th>
<th>INJECTABLE</th>
<th>ANTIBODY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polymer ring inserted into the vagina releases antiretroviral drug over time.</td>
<td>Device implanted in the body releases antiretroviral drug over time.</td>
<td>Long-acting antiretroviral drug is injected into the body.</td>
<td>Antibody is infused or injected into the body.</td>
</tr>
</tbody>
</table>

How many products are under investigation?

dapivirine IVR (MTN 025/HOPE and MTN 034/REACH clinical trials)
tenofovir IVR (CONFIRM)
Truvada IVR (Oak Crest Institute of Science)
cabotegravir (SLAP-HIV project)
dolutegravir (University of North Carolina)
tenofovir alafenamide (Oak Crest Institute of Science)
tenofovir alafenamide & emtricitabine (Houston Methodist Research Institute)
cabotegravir (HPTN 077, 083 & 084 clinical trials)
10E8VLS (VRC 610 clinical trial)
CAP256V2LS (NIAID VRC & CAPRISA)
N6LS (VRC 609 clinical trial)
Sanofi trispecific antibody (HVTN 129/HPTN 088 clinical trial)
VRC01 (AMP Studies, HVTN 116 & IMPAACT P1112 clinical trials)
VRC01LS (HVTN 116 & IMPAACT P1112 clinical trials)
VRC07-52LS (VRC 610 & HVTN 127/HPTN 087 clinical trials)

At what stage is this research?

Safety studies & manufacturing Design and development Human studies

For more on the latest advances in HIV prevention research, visit: